Amicus Therapeutics (FOLD) Competitors $7.64 -0.36 (-4.51%) As of 11:48 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock FOLD vs. EXEL, EXAS, RGEN, HALO, MDGL, ALKS, IONS, LGND, DVAX, and BCRXShould you be buying Amicus Therapeutics stock or one of its competitors? The main competitors of Amicus Therapeutics include Exelixis (EXEL), Exact Sciences (EXAS), Repligen (RGEN), Halozyme Therapeutics (HALO), Madrigal Pharmaceuticals (MDGL), Alkermes (ALKS), Ionis Pharmaceuticals (IONS), Ligand Pharmaceuticals (LGND), Dynavax Technologies (DVAX), and BioCryst Pharmaceuticals (BCRX). These companies are all part of the "biotechnology" industry. Amicus Therapeutics vs. Exelixis Exact Sciences Repligen Halozyme Therapeutics Madrigal Pharmaceuticals Alkermes Ionis Pharmaceuticals Ligand Pharmaceuticals Dynavax Technologies BioCryst Pharmaceuticals Amicus Therapeutics (NASDAQ:FOLD) and Exelixis (NASDAQ:EXEL) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, community ranking, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and profitability. Which has better earnings and valuation, FOLD or EXEL? Exelixis has higher revenue and earnings than Amicus Therapeutics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmicus Therapeutics$528.30M4.65-$151.58M-$0.18-44.44Exelixis$2.17B4.73$521.27M$1.7720.72 Does the MarketBeat Community favor FOLD or EXEL? Exelixis received 88 more outperform votes than Amicus Therapeutics when rated by MarketBeat users. However, 72.98% of users gave Amicus Therapeutics an outperform vote while only 68.58% of users gave Exelixis an outperform vote. CompanyUnderperformOutperformAmicus TherapeuticsOutperform Votes53272.98% Underperform Votes19727.02% ExelixisOutperform Votes62068.58% Underperform Votes28431.42% Which has more volatility & risk, FOLD or EXEL? Amicus Therapeutics has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500. Comparatively, Exelixis has a beta of 0.57, meaning that its stock price is 43% less volatile than the S&P 500. Do analysts recommend FOLD or EXEL? Amicus Therapeutics presently has a consensus price target of $16.75, suggesting a potential upside of 109.38%. Exelixis has a consensus price target of $37.59, suggesting a potential upside of 2.48%. Given Amicus Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Amicus Therapeutics is more favorable than Exelixis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amicus Therapeutics 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78Exelixis 1 Sell rating(s) 8 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is FOLD or EXEL more profitable? Exelixis has a net margin of 24.04% compared to Amicus Therapeutics' net margin of -10.62%. Exelixis' return on equity of 23.52% beat Amicus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Amicus Therapeutics-10.62% 12.44% 2.60% Exelixis 24.04%23.52%17.95% Does the media prefer FOLD or EXEL? In the previous week, Exelixis had 19 more articles in the media than Amicus Therapeutics. MarketBeat recorded 33 mentions for Exelixis and 14 mentions for Amicus Therapeutics. Exelixis' average media sentiment score of 1.36 beat Amicus Therapeutics' score of 1.11 indicating that Exelixis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amicus Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Exelixis 23 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders hold more shares of FOLD or EXEL? 85.3% of Exelixis shares are held by institutional investors. 2.2% of Amicus Therapeutics shares are held by insiders. Comparatively, 2.9% of Exelixis shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. SummaryExelixis beats Amicus Therapeutics on 14 of the 18 factors compared between the two stocks. Remove Ads Get Amicus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FOLD vs. The Competition Export to ExcelMetricAmicus TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.46B$6.72B$5.53B$7.50BDividend YieldN/A2.80%4.86%4.05%P/E Ratio-44.446.9923.2318.08Price / Sales4.65198.60362.7586.83Price / CashN/A65.6738.1634.64Price / Book12.705.926.493.99Net Income-$151.58M$142.37M$3.21B$247.18M7 Day Performance-5.10%-7.24%-4.90%-4.25%1 Month Performance-12.18%-10.45%-0.07%-6.87%1 Year Performance-30.19%-14.58%6.45%-3.73% Amicus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FOLDAmicus Therapeutics4.1822 of 5 stars$7.64-4.5%$16.75+119.3%-29.6%$2.35B$528.30M-42.47480Analyst RevisionNews CoveragePositive NewsGap DownEXELExelixis4.4858 of 5 stars$37.72+2.1%$37.59-0.3%+54.8%$10.56B$2.17B21.311,220Positive NewsGap DownEXASExact Sciences4.4156 of 5 stars$47.09+3.2%$70.83+50.4%-39.2%$8.75B$2.76B-8.456,400Positive NewsRGENRepligen4.6944 of 5 stars$145.15+3.7%$178.64+23.1%-31.4%$8.15B$634.44M-284.612,020HALOHalozyme Therapeutics4.1863 of 5 stars$64.02-1.7%$62.78-1.9%+53.9%$7.91B$1.02B18.66390Positive NewsMDGLMadrigal Pharmaceuticals3.5101 of 5 stars$346.40+1.4%$378.44+9.3%+33.4%$7.65B$180.13M-13.8190Positive NewsGap DownALKSAlkermes4.5287 of 5 stars$34.84+0.7%$38.46+10.4%+20.2%$5.67B$1.56B16.051,800Gap DownIONSIonis Pharmaceuticals4.2386 of 5 stars$33.45+1.6%$59.44+77.7%-34.9%$5.32B$705.14M-11.00800Analyst ForecastGap DownLGNDLigand Pharmaceuticals4.3302 of 5 stars$111.67+3.3%$147.00+31.6%+38.0%$2.15B$167.13M44.4980Short Interest ↑Positive NewsGap DownDVAXDynavax Technologies4.03 of 5 stars$13.84+0.1%$21.50+55.3%+5.4%$1.72B$277.25M76.89350Positive NewsBCRXBioCryst Pharmaceuticals4.2733 of 5 stars$8.05+0.9%$15.57+93.4%+55.0%$1.68B$450.71M-13.20530Short Interest ↑Gap Down Remove Ads Related Companies and Tools Related Companies EXEL Alternatives EXAS Alternatives RGEN Alternatives HALO Alternatives MDGL Alternatives ALKS Alternatives IONS Alternatives LGND Alternatives DVAX Alternatives BCRX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FOLD) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredTrump’s Great Society Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amicus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amicus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy FOLD Stock Free FOLD Stock Alerts